November 24, 2021 -- Philogen and Janssen Biotech will collaborate to discover new small molecules of pharmaceutical interest using Philogen's lead-generation technologies. Specifically, Philogen and Janseen will work to identify small molecule compounds that bind to specific targets using Philogen's patented DNA-encoded chemical library technology platform.
Philogen's primary focus is developing anti-cancer therapeutics barring the normal tissue. Its strategy is to deliver bioactive agents (cytokines or drugs) to the site of disease using antibodies and other ligands that target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical compounds for use in an array of disease indications, according to the companies.
Under the agreement, Janssen may exercise the option in the future to use identified ligands as candidates for further drug discovery and development activities.
No financial details of the agreement were disclosed.